Alnylam Pharmaceuticals Stumbles as 252nd in Volume Amid Pipeline Hiccups and Debt Worries

On September 23, 2025, , , . The biopharma firm’s shares faced pressure amid mixed signals from its therapeutic pipeline and broader market volatility.

Recent developments highlighted Alnylam’s ongoing challenges in advancing its RNAi therapeutics. , dampening investor optimism. , analysts noted the lack of near-term catalysts to offset long-term execution risks.

Market participants also scrutinized Alnylam’s capital allocation strategy. , though the company emphasized the funding’s role in supporting late-stage programs. .

, 2022, , , revealed limitations in evaluating such approaches. . Simplified alternatives, , or utilizing external platforms like PortfolioLab, remain necessary to fully assess the strategy’s viability.